Top

14-06-2015 | PARP inhibitors | Book chapter | Article

18. Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations

Authors: Kiranjit K. Dhillon, Toshiyasu Taniguchi

Publisher: Springer International Publishing

Abstract

PARP inhibitors are a promising class of chemotherapy agents that have shown efficacy in the treatment of BRCA1/2-deficient tumors. Treatment with these small molecule inhibitors in a homologous recombination repair (HRR) deficient background results in synthetic lethality. However, cancer cells can become resistant to PARP inhibitors by several different mechanisms. A major mechanism of PARP inhibitor resistance is restoration of functional BRCA1/2 by secondary BRCA1/2 mutation. BRCA1/2 restoration cancels synthetic lethality as it leads to functional HRR-mediated DNA repair. Loss of 53BP1 expression in BRCA1-mutated cancer cells can also lead to PARP inhibitor resistance by partial restoration of HRR. Additional mechanisms of PARP inhibitor resistance include increased P-glycoprotein expression that results in increased efflux of the drug and loss of PARP1 expression that prevents formation of toxic DNA-PARP1 lesions. Here, we focus on PARP inhibitor resistance by BRCA1/2 restoration and potential clinical implications of this phenomenon. We also briefly discuss the other known and possible mechanisms of PARP resistance.

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913–917PubMedCrossRef

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921PubMedCrossRef

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134. doi:NEJMoa0900212 [pii] 10.1056/NEJMoa0900212PubMedCrossRef

Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235–244. doi:10.1016/S0140-6736(10)60892-6PubMedCrossRef

Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14(9):882–892. doi:10.1016/S1470-2045(13)70240-7PubMedCrossRef

Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451(7182):1116–1120. doi:10.1038/nature06633PubMedCentralPubMedCrossRef

Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182):1111–1115PubMedCrossRef

Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, Wurz K, Higgins J, Villegas E, Taniguchi T (2009) Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 69(16):6381–6386. doi:0008-5472.CAN-09-1178 [pii] 10.1158/0008-5472.CAN-09-1178PubMedCentralPubMedCrossRef

Smulson ME, Schein P, Mullins DW Jr, Sudhakar S (1977) A putative role for nicotinamide adenine dinucleotide-promoted nuclear protein modification in the antitumor activity of N-methyl-N-nitrosourea. Cancer Res 37(9):3006–3012PubMed

10.

Benjamin RC, Gill DM (1980) Poly(ADP-ribose) synthesis in vitro programmed by damaged DNA. A comparison of DNA molecules containing different types of strand breaks. J Biol Chem 255(21):10502–10508PubMed

11.

Berger NA, Sikorski GW, Petzold SJ, Kurohara KK (1980) Defective poly(adenosine diphosphoribose) synthesis in xeroderma pigmentosum. Biochemistry 19(2):289–293PubMedCrossRef

12.

Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G (1998) XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18(6):3563–3571PubMedCentralPubMed

13.

Schreiber V, Ame JC, Dolle P, Schultz I, Rinaldi B, Fraulob V, Menissier-de Murcia J, de Murcia G (2002) Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277(25):23028–23036. doi:10.1074/jbc.M202390200PubMedCrossRef

14.

Leppard JB, Dong Z, Mackey ZB, Tomkinson AE (2003) Physical and functional interaction between DNA ligase III alpha and poly(ADP-Ribose) polymerase 1 in DNA single-strand break repair. Mol Cell Biol 23(16):5919–5927PubMedCentralPubMedCrossRef

15.

Moynahan ME, Chiu JW, Koller BH, Jasin M (1999) Brca1 controls homology-directed DNA repair. Mol Cell 4(4):511–518PubMedCrossRef

16.

Moynahan ME, Pierce AJ, Jasin M (2001) BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7(2):263–272PubMedCrossRef

17.

Yu X, Baer R (2000) Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor. J Biol Chem 275(24):18541–18549PubMedCrossRef

18.

Chen L, Nievera CJ, Lee AY, Wu X (2008) Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J Biol Chem 283(12):7713–7720. doi:M710245200 [pii] 10.1074/ jbc.M710245200PubMedCrossRef

19.

Zhang F, Fan Q, Ren K, Andreassen PR (2009) PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 7(7):1110–1118. doi:1541-7786.MCR-09-0123 [pii] 10.1158/1541-7786.MCR-09-0123PubMedCrossRef

20.

Tischkowitz M, Xia B (2010) PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res 70(19):7353–7359. doi:10.1158/0008-5472.CAN-10-1012PubMedCentralPubMedCrossRef

21.

Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, Saigo PE, Almadrones LA, Barakat RR, Brown CL, Chi DS, Curtin JP, Poynor EA, Hoskins WJ (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283(17):2260–2265PubMedCrossRef

22.

Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97(9):2187–2195PubMedCrossRef

23.

Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S (2008) Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 26(1):20–25PubMedCrossRef

24.

Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, Hooning MJ, Berns EM, Jager A, Collee M, Burger CW, Seynaeve C (2011) Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 22(6):1346–1352. doi:mdq628 [pii]10.1093/annonc/mdq628PubMedCrossRef

25.

Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME (2008) “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26(34):5530–5536. doi:JCO.2008.16.1703 [pii]10.1200/JCO.2008.16.1703PubMedCrossRef

26.

Kraakman-van der Zwet M, Overkamp WJ, van Lange RE, Essers J, van Duijn-Goedhart A, Wiggers I, Swaminathan S, van Buul PP, Errami A, Tan RT, Jaspers NG, Sharan SK, Kanaar R, Zdzienicka MZ (2002) Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol 22(2):669–679PubMedCentralPubMedCrossRef

27.

McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A (2005) BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 4(9):934–936PubMedCrossRef

28.

Chen Y, Zhang L, Hao Q (2013) Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet 288(2):367–374. doi:10.1007/s00404-013-2856-2PubMedCrossRef

29.

Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12(9):852–861. doi:10.1016/S1470-2045(11)70214-5PubMedCrossRef

30.

Underhill C, Toulmonde M, Bonnefoi H (2011) A review of PARP inhibitors: from bench to bedside. Ann Oncol 22(2):268–279. doi:10.1093/annonc/mdq322PubMedCrossRef

31.

Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28(15):2512–2519. doi:10.1200/JCO.2009.26.9589PubMedCrossRef

32.

Han S, Brenner JC, Sabolch A, Jackson W, Speers C, Wilder-Romans K, Knudsen KE, Lawrence TS, Chinnaiyan AM, Feng FY (2013) Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Neoplasia 15(10):1207–1217PubMedCentralPubMedCrossRef

33.

Kalev P, Simicek M, Vazquez I, Munck S, Chen L, Soin T, Danda N, Chen W, Sablina A (2012) Loss of PPP2R2 A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition. Cancer Res 72(24):6414–6424. doi:10.1158/0008-5472.CAN-12-1667PubMedCrossRef

34.

Williamson CT, Muzik H, Turhan AG, Zamo A, O’Connor MJ, Bebb DG, Lees-Miller SP (2010) ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 9(2):347–357. doi:10.1158/1535-7163.MCT-09-0872PubMedCentralPubMedCrossRef

35.

Williamson CT, Kubota E, Hamill JD, Klimowicz A, Ye R, Muzik H, Dean M, Tu L, Gilley D, Magliocco AM, McKay BC, Bebb DG, Lees-Miller SP (2012) Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med 4(6):515–527. doi:10.1002/emmm.201200229PubMedCentralPubMedCrossRef

36.

Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T (2010) The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116(22):4578–4587. doi:10.1182/blood-2010-01-265769PubMedCrossRef

37.

Postel-Vinay S, Bajrami I, Friboulet L, Elliott R, Fontebasso Y, Dorvault N, Olaussen KA, Andre F, Soria JC, Lord CJ, Ashworth A (2013) A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene 32(47):5377–5387. doi:10.1038/onc.2013.311PubMedCrossRef

38.

Zhang JX, Li DQ, He AR, Motwani M, Vasiliou V, Eswaran J, Mishra L, Kumar R (2012) Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology 55(6):1840–1851. doi:10.1002/hep.25566PubMedCentralPubMedCrossRef

39.

Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20(3):764–775. doi:10.1158/1078-0432.CCR-13-2287PubMedCentralPubMedCrossRef

40.

Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ (2012) Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat 135(2):505–517. doi:10.1007/s10549-012-2188-0PubMedCentralPubMedCrossRef

41.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66(16):8109–8115. doi:10.1158/0008-5472.CAN-06-0140PubMedCrossRef

42.

Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Breast Cancer Susceptibility Collaboration, Eccles D, Evans DG, Renwick A, Seal S, Lord CJ, Ashworth A, Reis-Filho JS, Antoniou AC, Rahman N (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43(9):879–882. doi:10.1038/ng.893PubMedCrossRef

43.

Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ (2007) HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A 104(49):19482–19487. doi:10.1073/pnas.0707828104PubMedCentralPubMedCrossRef

44.

Hirschhorn R (2003) In vivo reversion to normal of inherited mutations in humans. J Med Genet 40(10):721–728PubMedCentralPubMedCrossRef

45.

Ikeda H, Matsushita M, Waisfisz Q, Kinoshita A, Oostra AB, Nieuwint AW, De Winter JP, Hoatlin ME, Kawai Y, Sasaki MS, D'Andrea AD, Kawakami Y, Joenje H (2003) Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. Cancer Res 63(10):2688–2694PubMed

46.

Wiegant WW, Overmeer RM, Godthelp BC, van Buul PP, Zdzienicka MZ (2006) Chinese hamster cell mutant, V-C8, a model for analysis of Brca2 function. Mutat Res 600(1–2):79–88. doi:10.1016/j.mrfmmm.2006.03.001PubMedCrossRef

47.

Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68(8):2581–2586PubMedCentralPubMedCrossRef

48.

Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM (2011) Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 29(22):3008–3015. doi:10.1200/JCO.2010.34.2980PubMedCentralPubMedCrossRef

49.

Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A (2013) Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol 229(3):422–429. doi:10.1002/path.4140PubMedCrossRef

50.

Dhillon KK, Swisher EM, Taniguchi T (2011) Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci 102(4):663–669. doi:10.1111/j.1349-7006.2010.01840.xPubMedCentralPubMedCrossRef

51.

Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A, Green P, Solomon E, Morris JR, Jonkers J (2011) BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 20(6):797–809. doi:10.1016/j.ccr.2011.11.014PubMedCrossRef

52.

Cancer Genome Atlas Research N (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609–615. doi:10.1038/nature10166CrossRef

53.

Tutt A, Bertwistle D, Valentine J, Gabriel A, Swift S, Ross G, Griffin C, Thacker J, Ashworth A (2001) Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. Embo J 20(17):4704–4716. doi:10.1093/emboj/20.17.4704PubMedCentralPubMedCrossRef

54.

McVey M, Lee SE (2008) MMEJ repair of double-strand breaks (director’s cut): deleted sequences and alternative endings. Trends Genet 24(11):529–538. doi:10.1016/j.tig.2008.08.007PubMedCrossRef

55.

Xie K, Doles J, Hemann MT, Walker GC (2010) Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci U S A 107(48):20792–20797. doi:10.1073/pnas.1011412107PubMedCentralPubMedCrossRef

56.

Zhong Q, Chen CF, Chen PL, Lee WH (2002) BRCA1 facilitates microhomology-mediated end joining of DNA double strand breaks. J Biol Chem 277(32):28641–28647. doi:10.1074/jbc.M200748200PubMedCrossRef

57.

Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 105(44):17079–17084. doi:10.1073/pnas.0806092105PubMedCentralPubMedCrossRef

58.

Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, Xu X, Deng CX, Finkel T, Nussenzweig M, Stark JM, Nussenzweig A (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141(2):243–254. doi:10.1016/j.cell.2010.03.012PubMedCentralPubMedCrossRef

59.

Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J (2010) 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 17(6):688–695. doi:10.1038/nsmb.1831PubMedCentralPubMedCrossRef

60.

Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S (2013) Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 3(1):68–81. doi:10.1158/2159-8290.CD-12-0049PubMedCrossRef

61.

Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D’Andrea AD (2001) Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7(2):249–262PubMedCrossRef

62.

Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI (2013) Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A 110(42):17041–17046. doi:10.1073/pnas.1305170110PubMedCentralPubMedCrossRef

63.

Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell J, Lord CJ, Ashworth A (2013) A genetic screen using the PiggyBac transposon in haploid cells identifies PARP1 as a mediator of olaparib toxicity. PLoS ONE 8(4):e61520. doi:10.1371/journal.pone.0061520PubMedCentralPubMedCrossRef

64.

Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72(21):5588–5599. doi:10.1158/0008-5472.CAN-12-2753PubMedCentralPubMedCrossRef

65.

Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O’Connor MJ, Lukas J, Bartek J (2012) Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 11(20):3837–3850. doi:10.4161/cc.22026PubMedCentralPubMedCrossRef

66.

Jacquemont C, Taniguchi T (2007) Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 67(15):7395–7405. doi:10.1158/0008-5472.CAN-07-1015PubMedCrossRef

67.

Deans AJ, Khanna KK, McNees CJ, Mercurio C, Heierhorst J, McArthur GA (2006) Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res 66(16):8219–8226. doi:10.1158/0008-5472.CAN-05-3945PubMedCrossRef

68.

Dungey FA, Caldecott KW, Chalmers AJ (2009) Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther 8(8):2243–2254. doi:10.1158/1535-7163.MCT-09-0201PubMedCentralPubMedCrossRef

Medicine Matters Oncology

Abstract